RxDoctor Payments Data

Ingela Pezzolesi, MD

Family Medicine · Silverdale, WANPI 1235167180

Payments from drug & device makers

$1,362in general payments, 2019–2025

Across 90 payments — averaging $15.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$242
  • Bayer$239
  • AbbVie$175
  • Pfizer$148
  • Astellas Pharma US Inc$124
  • Novo Nordisk$116
  • plus $317 from 8 others

What the payments were for

  • Food & beverage$1,07079%
  • Education$29221%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,362 in reported general payments places this provider in the 85th percentile of 2,275 family medicine providers in Washington.

See all family medicine providers in Washington

Medicare billing

Part B allowed, 2024
$386,169
Medicare patients
615
Services billed
8,715

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide85$103,476
FarxigaDapagliflozin Propanediol45$48,317
JardianceEmpagliflozin27$39,557
JanuviaSitagliptin Phosphate36$39,524
XareltoRivaroxaban33$32,816
MyrbetriqMirabegron27$23,507
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$20,746
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr25$11,875
Breo ElliptaFluticasone/Vilanterol19$7,316
OxycontinOxycodone Hcl13$6,310
Estradiol82$5,912
Fluticasone-SalmeterolFluticasone Propion/Salmeterol35$5,388
Levothyroxine Sodium462$4,955
PremarinEstrogens, Conjugated15$4,897
MultaqDronedarone Hcl12$4,784

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$242$48,31745 claims
MerckJanuvia, Dulera$24$43,49948 claims
Boehringer IngelheimJardiance$109$39,55727 claims
Astellas Pharma US IncMyrbetriq$124$23,50727 claims
PfizerPremarin$148$4,89715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,275 family medicine providers in Washington.

Other family medicine in Silverdale

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →